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ABSTRACT 
Background & Aims: Liver fibrosis, an important health concern associated to chronic 
liver injury that provides a permissive environment for cancer development, is 
characterized by accumulation of extracellular matrix components mainly derived from 
activated hepatic stellate cells (HSCs). Axl, a receptor tyrosine kinase, and its ligand 
Gas6 are involved in cell differentiation, immune response and carcinogenesis. 
Methods: HSCs were obtained from wild type and Axl-/- mice, treated with recombinant 
Gas6 protein (rGas6), Axl siRNAs or the Axl inhibitor BGB324, and analyzed by 
western blot and real-time PCR. Experimental fibrosis was studied in CCl4-treated wild 
type and Axl-/- mice, and in combination with Axl inhibitor. Gas6 and Axl serum levels 
were measured in alcoholic liver disease (ALD) and hepatitis C virus (HCV) patients. 
Results: In primary mouse HSCs, Gas6 and Axl levels paralleled HSC activation. rGas6 
phosphorylated Axl and AKT prior to HSC phenotypic changes, while Axl siRNA 
silencing reduced HSC activation. Moreover, BGB324 blocked Axl/AKT 
phosphorylation and diminished HSC activation. In addition, Axl KO mice displayed 
decreased HSC activation in vitro and liver fibrogenesis after chronic damage by CCl4 
administration. Similarly, BGB324 reduced collagen deposition and CCl4-induced liver 
fibrosis in mice. Importantly, Gas6 and Axl serum levels increased in ALD and HCV 
patients, inversely correlating with liver functionality. Conclusions: The Gas6/Axl axis 
is required for full HSC activation. Gas6 and Axl serum levels increase in parallel to 
chronic liver disease progression. Axl targeting may be a therapeutic strategy for liver 
fibrosis management.  
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INTRODUCTION 
Activation of hepatic stellate cells (HSCs) is responsible for the liver fibrosis associated 
to chronic liver injury of any etiology, being HSCs the main collagen-producing cells in 
the damaged liver [1,2]. Liver fibrosis, critical pre-stage in the development of liver 
cirrhosis, may lead to hepatic transplantation or promote a favorable microenvironment 
for cancer development [3]. HSCs transform during chronic liver injury from a 
quiescent state into a myofibroblast-like phenotype, which proliferate and migrate 
towards areas of necrosis and regeneration [4,5]. Activated HSCs alter extracellular 
matrix (ECM) composition due to the up-regulation of proteins such as α-smooth 
muscle actin (α-SMA), interstitial collagens such as Collagen 1A1 (COL1A1), and 
matrix metalloproteinases (MMPs) such as MMP9, as well as tissue inhibitor of 
metalloproteinases (TIMPs), and proteoglycans. Activated HSCs also generate hepatic 
cytokines such as TGF-β, PDGF, CTGF, FGF, HGF, and VEGF, and recruit 
inflammatory cells, mono- and polymorphonuclear leukocytes that produce 
chemokines, including MCP-1, RANTES, CCL21, CCR5. Although HSC critical role in 
liver fibrosis was proposed a decade ago [6], recent data demonstrates that irrespective 
of the underlying etiology of liver disease, the majority of myofibroblasts come from 
the liver-resident HSC population [7]. Moreover, after cessation of the fibrotic 
triggering insult, around 50% of the activated HSCs survive in an apparently quiescent 
state, being primed to quickly reactivate into myofibroblasts in response to fibrogenic 
stimuli [8,9]. Therefore, effective antifibrotic therapies aimed to inhibit activated HSCs, 
although positive to prevent extracellular matrix deposition, may be insufficient to 
definitely revert fibrosis, probably requiring the elimination of activated HSCs for 
fibrosis resolution in the treatment of chronic liver disease. 
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Growth arrest-specific gene 6 (Gas6) product is a vitamin K-dependent protein that 
activates a family of receptor tyrosine kinases including Axl, MERTK and Tyro3, 
known as TAM receptors, whose immunologic and oncogenic properties have been 
described in detail [10,11]. Among them, Axl receptor signaling has been related to 
processes leading to cell differentiation and carcinogenesis. Gas6 possesses a high 
structural homology and sequence identity to the natural anticoagulant protein S (ProS). 
However, Gas6 and ProS have clearly different biological roles [12,13].   
In liver pathologies, a hepatoprotective role for Gas6 has been reported in 
ischemia/reperfusion-induced damage [14], and in the wound healing response to liver 
injury [15,16]. In normal liver, Gas6 is mainly expressed in Kupffer cells, while Axl is 
found in macrophages and in quiescent HSC [17]. Moreover, after acute CCl4 
administration increased Gas6 expression was observed in activated HSCs and 
macrophages, while Gas6 in vitro protection to HSCs was mediated by the Axl/PI3-
kinase/AKT pathway [17]. However, the role of Gas6/Axl signaling in chronic liver 
disease, the potential use of related proteins as serological markers of disease 
progression, and Gas6/Axl targeting in future liver therapies are aspects that merit 
further investigation. 
To do so, we used both a genetic model of Axl deficiency (Axl KO), and a 
pharmacologic approach, the Axl inhibitor BGB324 [18]. Our results revealed that Axl 
receptor is an interesting target to block HSC transformation in vitro and demonstrated 
the efficacy of both strategies, genetic and pharmacologic, to diminish experimental 
liver fibrosis after chronic administration of CCl4. Moreover, we analyzed data from 
patients at different stages of alcoholic liver disease (ALD) and HCV infection 
providing evidence of the involvement of the Gas6/Axl axis in human liver fibrosis, and 
showing the correlation between Gas6/Axl serum levels and liver dysfunction.  
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In conclusion, our results underscore a critical role of the Gas6/Axl in fibrogenesis and 
in the progression of chronic liver diseases, suggesting that therapies aimed to inhibit 
Axl signaling deserve to be undertaken for the treatment of liver fibrosis, particularly 
now that small molecule inhibitors of Axl have been tested in clinical trials for cancer 
treatment [19].  
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MATERIALS AND METHODS 
Animal procedures. All procedures were performed according to protocols approved by 
the Animal Experimentation Ethics Committee from the University of Barcelona. In 
vivo liver fibrogenesis was analyzed after chronic carbon tetrachloride (CCl4) 
administration. To this aim, wild type (WT) or Axl KO mice were treated with CCl4 at a 
dose of 5 ?l (10% CCl4 in corn oil)/g of body weight, by intraperitoneal injection twice 
a week for 5-6 weeks. Control animals received corn oil alone. Treatment with Axl 
inhibitor (BGB324) or vehicle (saline solution) was performed daily for the last 10 days 
of the study via oral gavage at a dose of 80 μg/g body weight. In previous experiments 
with rodents at similar doses, BGB324 reached serum concentration in the low 
micromolar range [18], being safe for animal treatment. Control animals received 
vehicle alone.  
HSCs isolation and culture. Wild type and Axl knockout mice livers (male, 8–10-week-
old littermates) (C57BL/6 strain) were perfused with collagenase and HSCs cultured as 
previously described [20,21]. Culture purity, assessed routinely by retinoid 
autofluorescence at 350 nm, was >95%. Lack of staining for F4/80 confirmed the 
absence of Kupffer cells. HSCs and LX2 human activated stellate cells [20,22] were 
cultured in DMEM supplemented with 10% FBS and antibiotics at 37 °C in a 
humidified atmosphere of 95% air and 5% CO2. Experiments to compare protein or 
mRNA content were always performed with cells extracted at the same time of culture, 
previously treated with  recombinant Gas6 (R&D), Axl inhibitor (BGB324, 
BerGenBio), or siRNA silencing (Santa Cruz) after Lipofectamine 2000 exposure for 
the indicated periods of time.  
SDS-PAGE and immunoblot analysis; RNA isolation and real time RT-PCR; In Vitro 
Small Interfering RNA Transfection; Nuclear extract isolation; Immunohistochemical 
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staining; and Liver collagen determination. These methods were performed as 
previously indicated [20,21,23] with modifications as specified in Supplemental 
Methods.   
Determination of Gas6, and soluble Axl (sAxl) levels. Measurements of Gas6 and sAxl 
human levels were carried out using commercial antibodies (R&D Systems) to develop 
specific ELISAs that use the sandwich technique as described [24]. Serum Gas6 mouse 
levels were determined using a commercial kit (DuoSet mGas6 ELISA, R&D). Serum 
sAxl mouse levels were determined by western blot. 
Human samples. a) The ALD study group comprised serum samples from 40 
individuals: 10 healthy normal adult controls (C) and 30 alcoholic patients with 
different degrees of liver disease as diagnosed after hepatic biopsy and Fibroscan 
measurement: 10 patients with initial fibrosis (Fibroscan score ≤ 7 KPa, mean = 
5.2±0.4) (F), 10 patients with compensated cirrhosis (CH) and, 10 patients with 
decompensated cirrhosis (DCH), 5 of them due to ascitis, 3 due to spontaneous bacterial 
peritonitis (SBP) and 2 due to gastrointestinal bleeding by esophageal varices and portal 
hypertension. Relevant biochemical data are shown in Table 1. b) The HCV study group 
comprised serum samples from 51 individuals at different stages of liver fibrosis (8 F0, 
15 F1, 17 F2 and 11 F3/F4), as stated by liver biopsies, before initiation of treatments. 
None of the HCV patients exhibited signs of decompensation. Relevant biochemical 
data are shown in Table 2. All subjects gave written informed consent in accordance 
with the Declaration of Helsinki, and the protocol, approved by ethical committees from 
the Hospital Clinic, followed ethical guidelines on handling human samples. 
Statistical analyses. Results are expressed as mean ± standard deviation, unless 
indicated, with the number of individual experiments detailed in Figure legends. 
Statistical comparisons were performed using unpaired 2-tailed Student’s t test or 1-way 
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ANOVA followed by Newman-Keuls Multiple Comparison Test (GraphPad Prism). A 
P value less than 0.05 was considered significant.  
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RESULTS 
TAM receptors and ligands levels during HSC activation 
Gas6 and ProS are the ligands of the tyrosine-kinase family of receptors named TAM 
(Tyro3, Axl and MERTK), which have been involved in numerous processes related to 
cell transformation and cancer. Since TAM receptor participation in HSC activation has 
not been explored, we analyzed the presence of transcriptional changes during HSC 
transdifferentiation in mouse-derived primary cultures of HSCs. A significant increase 
in the mRNA levels of Gas6, but not of ProS, was detected (Fig. 1A). In parallel, strong 
upregulation of Axl was observed, with no significant changes in MERTK levels (Fig. 
1B). Tyro3 mRNA levels were not detectable in these samples. Of note, increased 
secretion of Gas6 protein expression was confirmed in HSCs after different days in 
culture, as determined by ELISA in 24h cell-conditioned medium (Fig. 1C). Thus, the 
activation of WT HSCs is paralleled by an increase in expression of Axl, and the 
expression and secretion into the medium of Gas6.  
Axl is required for full HSC activation and proliferation in vitro 
To verify the repercussion of this correlation in HSC transformation, we analyzed the 
effect of reducing the expression of Axl in activated HSCs, by means of RNA silencing, 
and the consequences of Gas6 supplementation. Since primary HSCs are not easy to 
manipulate genetically, we used the LX2 human activated HSC cell line. LX2 cells with 
depleted Axl levels by siRNA transfection displayed a significant reduction in α-SMA 
levels (Fig. 2A). Moreover, we tested if recombinant Gas6 (rGas6) may further increase 
LX2 cells activation, and observed enhanced levels of α-SMA in LX2 exposed to rGas6 
for up to 3 days (Fig. 2B), compared to cells treated with vehicle (PBS). In addition, 
rGas6 administration induced a fast Axl and AKT phosphorylation in LX2 cells (Fig. 
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2C). Of note, Gas6-dependent AKT activation was responsible for the nuclear 
translocation of the anti-apoptotic NF-κB subunit p65, since it was detected in nuclear 
extracts of LX2 cells immediately after rGas6 administration, while PI3K inhibitor 
LY294002 blocked p65 nuclear upregulation. These results, in line with previous 
observations in activated HSCs [17], supported the participation of Gas6 activation on 
the proliferation and survival of HSCs via the AKT/NF-κB signaling pathways. 
However, since we also observed that rGas6 phosphorylated MERTK (Fig. 2C), at this 
point we cannot discard a potential role of MERTK in HSC signaling. 
To better examine Axl contribution, HSCs from Axl-/- mice were obtained, cultured and 
analyzed in comparison to WT HSCs. A significant reduction in the mRNA levels of the 
markers for HSC activation α-SMA and Col1a1 was observed in Axl deficient mice, as 
well as in TIMP-1 mRNA, while no differences for TGF-β levels were detected (Fig. 
2D). Indeed, Axl-/- HSCs showed decreased protein levels of α-SMA in vitro, showing a 
reduced activation state after 10 days and delayed proliferation, as manifested by 
MMP9 and PCNA levels, respectively (Fig. 2E). Although not all the variety of proteins 
induced during HSC activation are affected by Axl, as the absence of changes in TGF-β 
seem to indicate, taken as a whole, these results suggest that Axl signaling is required 
for full activation of HSCs in vitro.  
Axl deficiency diminished liver fibrosis induced by carbon tetrachloride 
To investigate if Gas6/Axl role in HSC activation in vitro may reflect a key 
participation of this system in the development of liver fibrosis, we used the chronic 
administration of CCl4 as a model to generate liver damage and fibrogenesis in mice. 
First, we wanted to analyze if Gas6 and Axl levels are modified in animals suffering 
liver fibrosis. After 5 weeks of CCl4 treatment mice exhibited increased Gas6 and sAxl 
serum levels compared to oil-treated animals (Fig. 3A), indicating that this pathway is 
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upregulated during CCl4-induced liver fibrosis. Second, we analyzed in Axl-/- mice the 
effect of CCl4 administration. After 5 weeks, liver hydroxyproline levels, indicative of 
collagen deposition, were significantly lower in Axl deficient animals treated with CCl4 
(Fig. 3B), suggesting reduced liver fibrosis as confirmed in liver sections after Sirius 
Red staining and quantification (Fig. 3C-D). In accordance, liver homogenates exhibited 
an increase in α-SMA and MMP9 after CCl4 administration that was reduced in Axl-/- 
mice (Fig. 3E) indicative of HSC activation and changes in ECM composition. 
Analogously, α-SMA stained liver slides from CCl4-treated Axl KO mice exhibited 
similar reduction (Suppl. Fig 1A). Finally, we checked the degree of liver injury to 
verify that the lower liver fibrosis observed in Axl KO mice is not a consequence of 
reduced hepatocellular damage induced by CCl4. Both WT and Axl deficient mice 
displayed similar ALT levels after CCl4 exposure, which allows discarding reduced 
liver fibrosis as a consequence of lesser hepatic damage.  
It has been proposed that Gas6 deficiency could lead to a decline in liver fibrosis after 
CCl4 exposure due to reduced macrophage recruitment [25]. Therefore, we decided to 
analyze potential differences in liver inflammation and immune cell recruitment to the 
liver. When we quantified the mRNA levels of inflammatory cytokines (TNF), 
chemokines (MCP-1) or neutrophil infiltration (MPO) in WT and Axl KO CCl4-treated 
mice they were similarly increased, as compared to their untreated controls (Suppl. Fig. 
1B, D). In addition, no changes in MPO staining were observed between WT and Axl-/- 
CCl4-treated animals (Suppl. Fig. 1C). However, a minor level of macrophages (F4/80) 
and newly-recruited monocytes/macrophages (CCR2) were detected in the livers of Axl 
deficient mice after CCl4 exposure (Suppl. Fig. 1D). These results support a role for the 
Gas6/Axl pathway in macrophage response to CCl4 exposure, as previously indicated 
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[25], and are in line with other models of tissue damage such as advanced 
atherosclerotic plaques in GAS6 deficient animals [26].   
BGB324, small molecule inhibitor of Axl, blocks HSC activation in vitro and 
reduces CCl4-induced liver fibrosis in WT mice 
Axl is an attractive target for the treatment of different human pathologies, particularly 
in cancer. Interestingly, a small molecule inhibitor of Axl (BGB324, BerGenBio) has 
entered clinical trials for cancer treatment. We tested the effect of BGB324 
administration for 24h on 7-day old WT HSC cells (Fig. 4A). Axl inhibitor 
administration was able to reduce the activation of primary HSCs, even inducing HSC 
elimination at higher doses in the micromolar range (Fig. 4A, upper image). This effect 
was specific for Axl inhibition since BGB324 administration did not affect MERTK 
phosphorylation (Fig. 4A, lower image), while effectively blocked AKT activation after 
short-term incubation with rGas6 (30 min., 200 ng/mL) (Fig. 4B).  
To analyze whether inhibition of Axl, using BGB324, may play a role in the 
progression of liver fibrogenesis, mice were injected CCl4 twice weekly to stimulate 
HSC activation and promote liver fibrosis. After 4 weeks, animals started receiving 
BGB324 co-treatment via oral gavage on a daily basis for 10 additional days. 
Determination of the hepatic hydroxyproline content showed a significant decrease in 
the accumulation of collagen fibers in animals treated with CCl4 that received Axl 
inhibitor compared to control animals (Fig. 4C). This result was confirmed after Sirius 
red staining, showing less deposition of collagen fibers in animals treated with BGB324 
and CCl4, compared to CCl4-vehicle treated mice (Fig. 4D), as denoted by the 
quantification of  collagen content in different sections (Fig. 4E). Moreover, mice that 
received BGB324 exhibited reduced levels of MMP9 and α-SMA after CCl4 exposure 
(Suppl. Fig 2A), and diminished α-SMA staining in liver slides compared to CCl4-
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treated mice without inhibitor administration (Suppl. Fig 2B), confirming changes in 
ECM composition and HSC activation. Of note, serum levels of ALT after CCl4 
administration were similar in vehicle and Axl inhibitor-treated mice indicating that the 
antifibrotic effect of BGB324 is not a consequence of reduced hepatocellular damage 
after chemical exposure (Fig. 4F). 
Interestingly, when we analyzed changes in liver inflammation and immune cell 
recruitment to the liver induced by BGB324, we obtained results in accordance with the 
data provided by the Axl KO mice. While a comparable degree of TNF, MCP-1 or 
neutrophil infiltration was observed in all CCl4-treated mice (Suppl. Fig. 2C,D), animals 
that received BGB324 exhibited decreased macrophage recruitment (Suppl. Fig. 2D), in 
line with previous results observed analyzing Gas6 KO mice [25].  
Serum levels of Gas6 and sAxl correlate with liver dysfunction in human ALD, and 
increased during HCV-induced fibrosis progression. 
Serum levels of Gas6 and/or sAxl have been related to cancer prognosis and to other 
pathologies, such as heart failure or sepsis [27,28]. Since our results point to Gas6/Axl 
axis as a relevant signaling pathway in liver fibrogenesis, we decided to evaluate this 
pathway in patients with different degrees of alcoholic liver disease (ALD) in which 
progression from asymptomatic fibrosis to decompensated cirrhosis is a well-studied 
process [29]. Therefore, we determined Gas6 and sAxl concentration in serum samples 
from alcoholic patients in initial (F0/F1) stages of liver fibrosis (F), patients with 
compensated (CH), and patients with decompensated hepatic cirrhosis (DCH), and 
compared them to control individuals (C). Both Gas6 and sAxl were found increased in 
serum levels of cirrhotic patients, showing close correlation with the severity of the 
disease, although behaving differently. Specifically, sAxl concentration was already 
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augmented in individuals with compensated cirrhosis compared to initial fibrosis (Fig. 
5B), while Gas6 levels were increased markedly in the DCH group (Fig. 5A).  
To verify this observation, we examined the relationship between the serum levels of 
Gas6 and sAxl compared to the Model for End-Stage Liver Disease (MELD) score 
system, which assigns a value calculated from different biochemical parameters altered 
in chronic liver disease. The analysis revealed a remarkable correlation between the 
MELD score and both proteins (Fig. 5C and 5D), being better for Gas6 serum levels 
(r2=0.78). Interestingly, we identified an algorithm containing sAxl and Gas6 that can 
achieve even stronger correlation (r2=0.86) with the MELD score (Fig. 5D), suggesting 
that the measurement of both proteins provides a better evaluation of liver functionality.  
However, since our ALD group contains only individuals with early F0/F1 fibrosis and 
with cirrhosis, compensated or decompensated, our measurements did not allow to 
verify an increase in the Gas6/Axl system during the progression of fibrosis, or to 
validate Gas6/Axl detection in other human hepatic pathologies. To do so, we analyzed 
Gas6 and sAxl levels in the serum of HCV patients at different stages of liver fibrosis 
before starting treatments (Figure 5E-F). Our data revealed that Gas6 levels were 
significantly different between individual with established fibrosis (F2) and patients 
with initial fibrosis (F0 and F1 groups). In addition, sAxl levels displayed significant 
changes between patients with F2 fibrosis and individuals with advanced fibrosis or 
cirrhosis (F3/F4 group). These findings underscore the relevance of the Gas6/Axl 
pathway during the development of ALD- and HCV-induced liver damage, supporting 
Gas6 and sAxl serum levels as indicative parameters of hepatic dysfunction and fibrosis 
development in liver disease.  
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DISCUSSION  
HSC transdifferentiation represents a crucial cell reprogramming event that shifts HSCs 
from a normal vitamin A-storing to an ECM-remodeling phenotype that favors 
tumorigenic development [4]. Despite recent progress in understanding the biology of 
HSCs, the mechanisms are not yet fully known. In fact, besides the 
treatment/withdrawal of the underlying cause, fibrosis regression in chronic liver 
diseases is not accomplished by any antifibrotic drug despite the experimental 
description of an array of pharmacological targets [1,5]. In this context, the 
characterization of the role of Gas6/Axl pathway in liver fibrosis, by participating in the 
activation of HSC may provide a new therapeutic target, not only for liver fibrosis, but 
also for different chronic liver diseases. Moreover, the existence of specific Axl 
inhibitors [30], already in clinical trials, may facilitate the biomedical translation of our 
results. 
Here, we used BGB324 (BerGenBio), an inhibitor of Axl ready to reach Phase Ib 
clinical trials for cancer treatment after showing good tolerability by healthy volunteers 
in doses up to 1.5 g/daily with a long plasma half-life [31]. BGB324 is highly specific 
for Axl inhibition, having exhibited >100-fold selectivity for Axl versus Abl and 50- 
and >100-fold selectivity over TAM family kinases MERTK and Tyro3, respectively, in 
cells-based assays [18]. In fact, we observed that at doses effective to block AKT 
phosphorylation and HSC activation, BGB324 did not alter MERTK phosphorylation 
by rGas6. Although, based in our data, we cannot discard other off-target effects of 
BGB324 administration, the highly similar results obtained between the Axl KO mice 
and the BGB324-treated mice suggest that the anti-fibrotic action of BGB324 is mainly 
due to Axl inhibition.  
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High levels of Axl expression have been observed in many types of cancer correlating 
with poor survival; among them glioblastoma multiforme [32], acute myeloid leukemia 
[33], breast cancer [34], osteosarcoma [35] and renal cell carcinoma [36]. Moreover, 
Axl activation is a mechanism of drug resistance to therapies targeting EGFR 
mechanism in lung cancer [37]. However, Axl and MERTK are also expressed by 
macrophages and dendritic cells, where they limit excessive immune response [10,38]. 
This aspect has raised concerns and could limit the use of TAM receptors as targets in 
cancer, in special since blockage of Axl/ MERTK promote the development of tumor 
growth in an inflammatory environment such as colon cancer [39], a tumor that benefits 
of a pro-inflammatory milieu similarly as liver cancer does. Importantly, this deleterious 
effect seems to require the simultaneous absence of both kinases (Axl and MERTK) 
activities [40], and BGB324 is already effective at doses that provide serum 
concentration in the low micromolar range, with minimal affinity for MERTK [18]. 
This observation is supported by our results in mice, not having detected inflammation 
in treated animals, displaying similar levels of neutrophil infiltration after CCl4 
administration. In fact, BGB324 has just received orphan-drug designation from FDA in 
the treatment of acute myeloid leukemia, supporting its good tolerability and lack of 
side-effects in clinical trials. In this sense, BGB324 accomplished a feature required to 
Axl inhibitors for systemic administration in cancer, particularly for hepatocellular 
carcinoma, to act without favoring a pro-carcinogenic background. Of note, other 
approaches to block Axl signaling are already under study, for instance an Axl 'decoy 
receptor' has been recently engineered, showing capacity to inhibit metastasis and 
cancer progression in vivo [40]. Therefore, BGB324 and other molecules that 
antagonize the Gas6/Axl pathway deserve to be further analyzed in the context of 
advanced liver fibrosis, and most probably of liver cancer development. 
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Several reports have positioned Gas6 as protective molecule against 
ischemia/reperfusion [14] and promoter of liver regeneration after acute liver damage 
[15,16], while its deficiency was associated to decreased liver fibrosis [25]. We 
considered using Gas6 KO mice to analyze Gas6/Axl system in HSC activation but 
previous results showing compensatory alterations such as Axl overexpression in the 
liver [25], refrained us to do it. In fact, we verified in murine Gas6-/- HSCs high 
expression of Axl, increased AKT phosphorylation, and elevated α-SMA levels, among 
other markers of HSC activation (Suppl. Fig. 3). Since Gas6/Axl axis is not blocked in 
Gas6-/- HSCs, we preferred to use the Axl KO mouse model instead. In this sense, our 
data targeting directly Axl underscore the importance of Gas6/Axl pathway in liver 
disease, being supported by similar results obtained after administration of the small 
molecule inhibitor BGB324.  
Although it has been reported an increase in Gas6/Axl proteins in patients with 
hepatocellular carcinoma from different etiologies [41], and sAxl levels are increased in 
end-stage heart failure patients undergoing heart transplantation [27], which frequently 
suffer cardiac fibrosis, Gas6/Axl as serological markers of liver function have not been 
previously proposed. We have confirmed in serum samples from ALD and HCV 
patients an enhancement in Gas6 and sAxl serum levels. Although we can not discard 
that the prominent increase in Gas6/Axl observed in these ALD cirrhotic patients may 
be partially due to a deficient liver protein clearance, the observation that a similar 
increase is also detected in fibrotic HCV patients, even in patients without cirrhosis, 
suggests otherwise. Moreover, an algorithm combination of Gas6 and sAxl levels 
display an excellent correlation with the degree of liver dysfunction in ALD patients 
determined by the MELD index (r2=0.86 for sAG index) suggesting that the 
measurement of both proteins provides additional information to analyze liver 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
Barcena et al. 
 19 
functionality. In this sense, we consider that preclinical research may also benefit from 
Gas6/Axl levels to measure fibrosis progression, since numerous targets for antifibrotic 
agents have problems to be analyzed or to enter early-phase clinical studies due to the 
lack of sensitive markers to follow the effects [42]. These results point to Gas6/sAxl 
determination as a significant diagnostic tool for chronic liver disease, and help us to 
position Gas6/Axl signaling pathway as a relevant in human liver pathology.  
In conclusion, Gas6/Axl is a profibrogenic route that is activated in patients with 
chronic liver disease. Therefore, small molecule inhibitors against Axl, that effectively 
eliminate HSC activation and reduce experimental fibrosis progression, may be an 
interesting therapeutic tool for future clinical trials.   
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TABLES 
Table 1. Biochemical data from the ALD patients and control serums analyzed for 
Gas6 and sAxl levels. For the control group, serums from 10 individuals (6 males and 4 
females with average age of 51.7±10.4) were used to measure Gas6 and Axl levels. 
Reference ranges for the each biochemical parameter are provided (right column), as 
established for normal individuals according to Hospital Clinic Core Lab (Barcelona, 
Spain). m=male; f=female. *, P≤0.05 vs. initial fibrosis group (F), #, P≤0.05 vs. 
cirrhotic compensated group (CH). 1-way ANOVA, Newman-Keuls Multiple 
Comparison Test.  
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Table 2. Biochemical data from the serum of HCV patients analyzed for Gas6 and 
sAxl levels. m=male; f=female. *, P≤0.05 vs. F0 group. #, P≤0.05 vs. F1 group. &, 
P≤0.05 vs. F2 group. 1-way ANOVA, Newman-Keuls Multiple Comparison Test.  
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FIGURE LEGENDS  
Figure 1. Gas6 and Axl levels are increased in WT HSCs during in vitro activation. 
A and B, mRNA expression level of Gas6, ProS, Axl and MERTK in HSCs at different 
times of in vitro activation, using β-actin as control. (n≥3). C, Gas6 protein levels 
released to fresh culture medium during 24 hours from HSCs at different time points of 
in vitro activation, detected by ELISA and corrected by cellular protein content. (n=3). 
*, P≤0.05, Student’s t test. 
Figure 2. Recombinant Gas6 induces HSC activation via Axl/AKT signaling and 
Axl deficiency reduces specific traits of HSC transdifferentiation. A, Axl silencing 
using specific siRNAs reduced Axl protein expression and HSC activation, quantified 
as the ratio α-SMA/β-actin at 48 hours post-transfection. (n=3). B, Representative 
western blot of α-SMA expression in LX2 treated with rGas6 (500 ng/ml) for 0 to 3 
days and quantification compared to β-actin content. (n=2). C, Representative western 
blot of phospho-Axl, phospho-MERTK, phospho-AKT, AKT and β-actin in total 
extracts, and p65 subunit of NF-κB and laminin in nuclear extracts from LX2 cells after 
rGas6 administration (500 ng/ml) and incubation with PI3K inhibitor LY294002. (n=2).  
D, mRNA expression level of α-SMA, Col1a1, TIMP-1 and TGF-β in HSCs from WT 
and Axl KO mice cultured in vitro for different times, using as β-actin control (n=3). E, 
Representative western blot of α-SMA, PCNA and MMP9 in protein extracts from WT 
and Axl KO mice HSCs after 10 days of in vitro culture (n=2). *, P≤0.05, Student’s t 
test. 
Figure 3. Gas6/Axl pathway is activated in CCl4-treated mice and Axl deficiency 
reduces CCl4-induced liver fibrosis. WT and Axl KO mice were i.p. treated with CCl4 
(twice a week) for 5 weeks. A, Gas6 and Axl levels in serum from WT mice treated 
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with CCl4 or vehicle (corn oil). Additionally, in WT and Axl KO mice treated with CCl4 
or vehicle were measured: B, Hydroxyproline levels in liver extracts. C, Representative 
images of liver sections after Sirius Red staining (20x). B, Sirius Red quantification of 
liver slides using Quantity One software in four random sections from each animal. E, 
Representative western blot of α-SMA, and MMP9 in liver extracts. E, ALT serum 
levels. *, P≤0.05, **, P≤0.01 vs. untreated WT mice, unless indicated. Student’s t test. 
Figure 4. Axl inhibitor BGB324 reduces HSC activation in vitro and liver fibrosis 
in CCl4-treated mice. A, Representative western blot of α-SMA expression in cell 
extract from WT HSCs treated with BGB324 (0-2 μM) for 24 hours or vehicle (lanes 1 
and 2) in upper image; and  phospho-Axl, phospho-MERTK, and β-actin in total 
extracts, from LX2 cells after rGas6 administration (500 ng/ml) and BGB324 pre-
incubation (30 min, 1 μM) in lower image (n=3). B, phospho-AKT, AKT and α-SMA 
expression in LX2 cells pre-treated with BGB324 (30 min, 1 μM) before administration 
of different doses of rGas6 for 30 min. (n=2). C, Hydroxyproline levels in liver extracts 
from WT mice treated with CCl4 or vehicle that received BGB324 (80 mg/kg, oral 
gavage, daily) or vehicle. D, Representative images of liver sections after Sirius Red 
staining (20x) from mice treated as above. E, Sirius Red quantification of liver slides. F, 
ALT serum levels from mice i.p. treated with CCl4 or vehicle that received Axl inhibitor 
or saline by oral gavage. *, P≤0.05, **, P≤0.01 vs. untreated WT mice, unless indicated. 
Student’s t test. 
Figure 5. Gas6 and sAxl serum levels are increased in alcoholic liver disease (ALD) 
and HCV-infected patients. A, Gas6 and B, Axl serum levels were measured in 
control individuals and patients with liver disease associated to alcohol consumption. 
Groups: C, control, F, Initial liver fibrosis (F0/F1), CH, hepatic cirrhosis, and DCH, 
decompensated hepatic cirrhosis. Additional data of patients is provided in Table 1. *, 
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P≤0.05, **, P≤0.001 between groups. 1-way ANOVA, Newman-Keuls Multiple 
Comparison Test. C, Correlation analysis between Gas6/sAxl and MELD score was 
calculated for all the ALD patients (n=30). D, sAG index, an algorithm calculated by 
multiplication of sAxl and Gas6 concentrations is plotted against MELD index. E, Gas6 
and F, Axl serum levels were measured in HCV patients with different fibrosis staging. 
Groups: F0 (no fibrosis), F1 (mild), F2 (moderate), and F3/F4 (severe 
fibrosis/cirrhosis). *, P≤0.05, **, P≤0.01 between groups. 1-way ANOVA, Newman-
Keuls Multiple Comparison Test. 
Figure 6. Schematic representation of Gas6/Axl role in liver fibrosis induced by 
chronic damage. In a mouse model of chemical-induced liver fibrosis Gas6/Axl 
signaling is induced. Increased Gas6 extracellular levels stimulate Axl activation in 
HSCs leading to HSC proliferation and phenotypic transformation via AKT 
phosphorylation and NF-κB nuclear translocation. Axl genetic deficiency (Axl KO 
mice) or Axl inhibition by BGB324 blocks fibrogenesis, effectively inhibiting Gas6-
induced HSC activation in vitro and reducing experimental liver fibrosis in vivo by 
eliminating activated HSCs. Therefore, small molecule inhibitors of Axl may be 
interesting compounds for the medical treatment of chronic liver fibrosis and prevention 
of HCC development.  
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HSCs from Gas6 KO mice exhibit Axl overexpression and increased activation. 
Representative western blots of protein extracts from WT and Gas6 KO HSCs to analyze 
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